-
Can different routes go the same way?
Time of Update: 2022-01-12
Author: Shencheng Hu GeThe protein arginine methyltransferase PRMT5 plays an important role in maintaining cell homeostasis. By catalyzing the symmetric dimethylation of arginine in more than 100 nuc
-
The State Food and Drug Administration cancels the registration certificate of disposable infusion set with needle medical device
Time of Update: 2022-01-12
On December 1, the State Food and Drug Administration issued an announcement stating that, in accordance with the Regulations on the Supervision and Administration of Medical Devices, the medical devi
-
Huadong Medicine: ADC's new drug treatment of ovarian cancer has reached the primary end point in overseas key clinical trials
Time of Update: 2022-01-12
The announcement showed that the SORAYA trial evaluated the safety and effectiveness of IMGN853 as a single-agent treatment of platinum-resistant ovarian cancer with high FRα expression.
-
Hengrui Medicine's new drug for dry eye disease successfully plans to be reported for listing in Phase III clinical trials
Time of Update: 2022-01-12
On November 30, Hengrui Medicine announced that SHR8058 eye drops for the treatment of meibomian gland dysfunction-related dry eye disease is a multi-center, randomized, double-blind, salt solution parallel controlled phase III clinical trial (SHR8058-301) that has achieved the main research endpoint results.
-
TOP20 retail Chinese patent medicinal plasters released, 4 products rose by over 30%, 11 brands with over 100 million dazzling
Time of Update: 2022-01-12
Xiaotong plaster hits a new high, Lingrui's 6 major brands are eye-catchingXiaotong plaster hits a new high, Lingrui's 6 major brands are eye-catchingSales of terminal pain relief plasters in physical pharmacies in Chinese cities in recent years (unit: 100 million yuan)Source: Mi Nei. com, China's urban physical pharmacy terminal competition patternXiaotong Plaster is the exclusive product of Tibet Qizheng Tibetan Medicine.
-
Bristol-Myers Squibb TYK2 inhibitor deucravacitinib enters review in the U.S. and Europe
Time of Update: 2022-01-12
S. anti-monopoly review of the Xenogene M&A case in 2019, BMS made the decision to sell Xenogene's fast-growing best-selling oral anti-inflammatory drug Otezla to Amgen to support the asset deucravacitinib, which was in phase 3 clinical development at the time .
-
Can Hengrui fight the PD-1 again?
Time of Update: 2022-01-11
On the same day, Hengrui Medicine registered a phase 1 clinical trial on the drug clinical trial registration and information disclosure platform website for subcutaneous injection of PD-1 antibody SHR-1901 .
PD-1/PD-L1 competition is upgraded again!Source: Drug Clinical Trial Registration and Information Disclosure PlatformSHR-1901 is the second PD-1 antibody developed by Hengrui Pharmaceuticals.
-
Pfizer's JAK1 inhibitor abrocitinib is approved in the EU for the treatment of moderate to severe atopic dermatitis
Time of Update: 2022-01-11
The JADE COMPARE trial is a randomized, double-blind, placebo-controlled study designed to evaluate two doses of Cibinqo (100 mg and 200 mg once a day) in 837 adults with moderate to severe atopic dermatitis in background topical medications In the efficacy and safety .
-
From medicine to concept, the next step in asthma treatment
Time of Update: 2022-01-11
In short, small airway dysfunction (SAD) is highly correlated with poor outcomes in asthma patients, but the treatment drugs are difficult to effectively reach all the large and small airways, resulting in poor overall asthma control .
-
The seventh batch of 87 nationally sourced varieties meet the conditions (list attached)
Time of Update: 2022-01-11
According to statistics from Huazhao Medical Network, in terms of product names, there are currently about 585 drugs that have been evaluated for consistency, of which about 63.
com, among the 3508 applications for consistency evaluation of generic drugs currently accepted, oral regular-release dosage forms and injections account for 47.
-
The registration of Artemisia annua pollen prickly liquid medicine has been accepted
Time of Update: 2022-01-11
On December 22, our company issued an announcement stating that it had obtained the "Notice of Acceptance" issued by the National Medical Products Administration a few days ago, and the company's regi
-
Decei Pharma and Bristol-Myers Squibb will jointly promote the clinical development of ATG-017 and Odivo
Time of Update: 2022-01-11
HK) today announced that the company and Bristol-Myers Squibb have reached a clinical cooperation agreement to jointly develop a joint evaluation of ATG-017 and Bristol-Myers Bristol-Myers Squibb's PD-1 checkpoint inhibitor Odivo® (Navulimab) is an open phase 1/2 clinical study on the safety, pharmacokinetics and preliminary efficacy of the treatment of advanced solid tumors .
-
Hansen Pharma's high-priced broad-spectrum antifungal drug was approved for Phase III clinical trials
Time of Update: 2022-01-11
In June 2021, ibrexafungerp (trade name: Brexafemme) was approved by the US FDA for the treatment of vulvovaginal candidiasis, becoming the first new antifungal approved in more than two decades, and the first and only vagina Non-azole therapy for yeast infections .
-
GSK leads the battle against infectious diseases in the vaccine battle to protect human health
Time of Update: 2022-01-11
Whether it is the immunization program implemented since the birth of a child, or the HPV vaccine for women in recent years and the shingles vaccine for middle-aged and elderly people, they are committed to the continuous upgrade and breakthrough of medical biotechnology to minimize people from suffering from diseases.
-
Three types of imitation inhalants of Jiming Trust are accepted by CDE
Time of Update: 2022-01-11
In 2019, Wang Chen, an academician of the Chinese Academy of Engineering and an expert in respiratory and critical care medicine, published research results in The Lancet, clarifying the prevalence of adult asthma in China: the prevalence of asthma in people aged 20 and above in China is 4.
-
Good news for patients with chronic diseases!
Time of Update: 2022-01-11
In response to relevant national policies, we are committed to enabling more Chinese patients to benefit from high-quality innovative drugs, providing adequate guarantees for standardized treatment of chronic diseases, and helping to achieve'Healthy China 2030' .
-
Overcome resistance!
Time of Update: 2022-01-11
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn December 15th, Nuvation announced that the US FDA has granted the company's CDK2/4/6 inhibitor NUV-422 fast track designation for the treatment of high-grade gliomas, including glioblastoma multiforme .
-
Novartis' long-acting lipid-lowering siRNA therapy twice a year is approved by the FDA for marketing
Time of Update: 2022-01-11
Article Source: Immediate Medicine NewsOn December 23, Novartis announced that the US FDA has approved Leqvio (inclisiran), which is currently the first and only one for lowering low-density lipoprotein cholesterol (also known as "bad cholesterol" or LDL-C).
Retrieved 2021-12-23, from https:// -releases/fda-approves-novartis-leqvio-inclisiran-first-in-class-sirna-to-lower-cholesterol-and-keep-it-low-with-two-doses-a-year-301450125.
-
Zhimeng Pharmaceutical's TLR8 agonist obtains FDA clinical trial approval
Time of Update: 2022-01-11
Source: Guanlan PharmaceuticalRecently, Zhimeng Pharmaceutical announced that the US FDA has approved the clinical trial application of its small molecule oral TLR8 agonist CB06-036 .
As a TLR8 agonist, CB06-036 has shown good selectivity, activity and safety in preclinical studies.
-
The first-line standard treatment of lymphoma can not be shaken for 20 years?
Time of Update: 2022-01-11
At the 2021 ASH Annual Meeting held recently, Vibotuzumab combined with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) compared with R-CHOP (rituximab) , Cyclophosphamide, doxorubicin, vincristine, prednisone) in the first-line treatment of diffuse large B-cell lymphoma (DLBCL) phase III POLARIX study as the "latest breakthrough study (LBA-1)" released detailed data, and Simultaneously published in NEJM[1] .
